| Attribute |
Value |
| 52 Week Change |
-0.52164006 |
| Address1 |
945 Concord Street |
| All Time High |
1,074.0 |
| All Time Low |
1.87 |
| Ask |
2.86 |
| Ask Size |
2 |
| Average Daily Volume10 Day |
17,520 |
| Average Daily Volume3 Month |
87,409 |
| Average Volume |
87,409 |
| Average Volume10Days |
17,520 |
| Beta |
2.202 |
| Bid |
1.59 |
| Bid Size |
2 |
| Book Value |
2.592 |
| City |
Framingham |
| Compensation As Of Epoch Date |
1,767,139,200 |
| Country |
United States |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
2.01 |
| Current Ratio |
7.435 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,790,726,400 |
| Day High |
2.09 |
| Day Low |
1.885 |
| Display Name |
Xenetic Biosciences |
| Dividend Date |
1,561,420,800 |
| Dividend Yield |
0.0 |
| Earnings Timestamp End |
1,755,288,000 |
| Earnings Timestamp Start |
1,754,942,400 |
| Ebitda Margins |
0.0 |
| Enterprise To Revenue |
-0.54 |
| Enterprise Value |
-1,761,972 |
| Eps Forward |
-0.66 |
| Eps Trailing Twelve Months |
-1.14 |
| Esg Populated |
0 |
| Exchange |
NCM |
| Exchange Data Delayed By |
15 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fifty Day Average |
3.1467 |
| Fifty Day Average Change |
-1.1366999 |
| Fifty Day Average Change Percent |
-0.36123556 |
| Fifty Two Week Change Percent |
-52.164005 |
| Fifty Two Week High |
4.939 |
| Fifty Two Week High Change |
-2.9290001 |
| Fifty Two Week High Change Percent |
-0.59303504 |
| Fifty Two Week Low |
1.87 |
| Fifty Two Week Low Change |
0.13999999 |
| Fifty Two Week Low Change Percent |
0.0748663 |
| Fifty Two Week Range |
1.87 - 4.939 |
| Financial Currency |
USD |
| First Trade Date Milliseconds |
1,467,293,400,000 |
| Float Shares |
1,891,088 |
| Forward Eps |
-0.66 |
| Forward P E |
-3.0454545 |
| Free Cashflow |
-1,174,761 |
| Full Exchange Name |
NasdaqCM |
| Full Time Employees |
2 |
| Fullday Change |
-0.089999914 |
| Fullday Change Percent |
-4.3062162 |
| Fullday Price |
2.01 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Gross Margins |
1.0 |
| Gross Profits |
3,260,777 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.114300005 |
| Held Percent Institutions |
0.06491 |
| Implied Shares Outstanding |
2,343,181 |
| Industry |
Biotechnology |
| Industry Disp |
Biotechnology |
| Industry Key |
biotechnology |
| Is Earnings Date Estimate |
1 |
| Language |
en-US |
| Last Fiscal Year End |
1,767,139,200 |
| Last Split Date |
1,684,108,800 |
| Last Split Factor |
1:10 |
| Long Business Summary |
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance. The company's product pipeline includes XBIO-015 for the treatment of pancreatic carcinoma and solid tumors; XBIO-020 for the treatment of solid tumors; and ErepoXen, which uses PolyXen platform technology for the treatment of anemia in chronic kidney disease (CKD) patients. It has a sublicensing agreement with Takeda Pharmaceutical Co. Ltd, as well as various research, development, license and supply agreements with Serum Institute of India, PJSC Pharmsynthez, and SynBio, LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts. |
| Long Name |
Xenetic Biosciences, Inc. |
| Market |
us_market |
| Market Cap |
4,709,794 |
| Market State |
POST |
| Max Age |
86,400 |
| Message Board Id |
finmb_23143993 |
| Most Recent Quarter |
1,782,777,600 |
| Net Income To Common |
-2,475,093 |
| Next Fiscal Year End |
1,798,675,200 |
| Non Diluted Market Cap |
5,857,952 |
| Open |
2.09 |
| Operating Cashflow |
-2,312,795 |
| Operating Margins |
-1.47092 |
| Payout Ratio |
0.0 |
| Phone |
781 778 7720 |
| Previous Close |
2.1 |
| Price Hint |
4 |
| Price To Book |
0.775463 |
| Price To Sales Trailing12 Months |
1.4443778 |
| Profit Margins |
-0.75905 |
| Quick Ratio |
7.231 |
| Quote Source Name |
Delayed Quote |
| Quote Type |
EQUITY |
| Recommendation Key |
none |
| Region |
US |
| Regular Market Change |
-0.089999914 |
| Regular Market Change Percent |
-4.2857103 |
| Regular Market Day High |
2.09 |
| Regular Market Day Low |
1.885 |
| Regular Market Day Range |
1.885 - 2.09 |
| Regular Market Open |
2.09 |
| Regular Market Previous Close |
2.1 |
| Regular Market Price |
2.01 |
| Regular Market Time |
1,792,094,400 |
| Regular Market Volume |
51,377 |
| Return On Assets |
-0.26798 |
| Return On Equity |
-0.4704 |
| Revenue Growth |
0.12 |
| Revenue Per Share |
1.57 |
| Sand P52 Week Change |
0.16440773 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Shares Outstanding |
2,343,181 |
| Shares Percent Shares Out |
0.0055 |
| Shares Short |
12,868 |
| Shares Short Previous Month Date |
1,788,134,400 |
| Shares Short Prior Month |
20,320 |
| Short Name |
Xenetic Biosciences, Inc. |
| Short Percent Of Float |
0.0057 |
| Short Ratio |
0.08 |
| Source Interval |
15 |
| State |
MA |
| Symbol |
XBIO |
| Total Cash |
6,471,766 |
| Total Cash Per Share |
2.762 |
| Total Debt |
0 |
| Total Revenue |
3,260,777 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
0.0 |
| Trailing Annual Dividend Yield |
0.0 |
| Trailing Eps |
-1.14 |
| Trailing Peg Ratio |
None |
| Triggerable |
1 |
| Two Hundred Day Average |
2.85528 |
| Two Hundred Day Average Change |
-0.84527993 |
| Two Hundred Day Average Change Percent |
-0.296041 |
| Type Disp |
Equity |
| Volume |
51,377 |
| Website |
https://www.xeneticbio.com |
| Zip |
1,701 |